UY40217A - Formas de sal y solvatos de antagonistas de mci-1 - Google Patents
Formas de sal y solvatos de antagonistas de mci-1Info
- Publication number
- UY40217A UY40217A UY0001040217A UY40217A UY40217A UY 40217 A UY40217 A UY 40217A UY 0001040217 A UY0001040217 A UY 0001040217A UY 40217 A UY40217 A UY 40217A UY 40217 A UY40217 A UY 40217A
- Authority
- UY
- Uruguay
- Prior art keywords
- salt
- mci
- solvates
- antagonists
- solvate forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263327659P | 2022-04-05 | 2022-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY40217A true UY40217A (es) | 2023-10-31 |
Family
ID=86386785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001040217A UY40217A (es) | 2022-04-05 | 2023-04-10 | Formas de sal y solvatos de antagonistas de mci-1 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12351588B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4504737A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025513774A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023249146A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3254998A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024012192A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202404983A (cg-RX-API-DMAC10.html) |
| UY (1) | UY40217A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023196360A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119255998A (zh) | 2022-05-04 | 2025-01-03 | 吉利德科学公司 | 特定mcl-1抑制剂的盐和多晶型物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
-
2023
- 2023-04-05 US US18/296,215 patent/US12351588B2/en active Active
- 2023-04-05 WO PCT/US2023/017504 patent/WO2023196360A1/en not_active Ceased
- 2023-04-05 JP JP2024558381A patent/JP2025513774A/ja active Pending
- 2023-04-05 CA CA3254998A patent/CA3254998A1/en active Pending
- 2023-04-05 EP EP23724438.9A patent/EP4504737A1/en active Pending
- 2023-04-05 AU AU2023249146A patent/AU2023249146A1/en active Pending
- 2023-04-06 TW TW112112762A patent/TW202404983A/zh unknown
- 2023-04-10 UY UY0001040217A patent/UY40217A/es unknown
-
2024
- 2024-10-02 MX MX2024012192A patent/MX2024012192A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025513774A (ja) | 2025-04-30 |
| CA3254998A1 (en) | 2023-10-12 |
| TW202404983A (zh) | 2024-02-01 |
| EP4504737A1 (en) | 2025-02-12 |
| WO2023196360A1 (en) | 2023-10-12 |
| MX2024012192A (es) | 2024-11-08 |
| US20230312602A1 (en) | 2023-10-05 |
| US12351588B2 (en) | 2025-07-08 |
| AU2023249146A1 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20200590A (es) | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas | |
| CO2022008359A2 (es) | Derivados de un inhibidor de fgfr | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| MX420195B (es) | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos | |
| MX2022001870A (es) | Combinaciones y composiciones de arn con propiedades inmunoestimuladoras disminuidas. | |
| EP4566612A3 (en) | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones | |
| MX2020011639A (es) | Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr). | |
| CU24564B1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
| MX2022000579A (es) | Combinaciones de un conjugado anticuerpo-farmaco anti-her2 y agentes quimioterapeuticos y los metodos de uso. | |
| CL2020002157A1 (es) | Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas. | |
| PE20250664A1 (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| CL2023002635A1 (es) | Derivados de 3h,4h,5h,6h,7h-pirimido[4,5-b][1,4]oxazin-4,6-diona como inhibidores de trpa1 | |
| CO2026000531A2 (es) | Macrociclos para el tratamiento de enfermedades autoinmunitarias | |
| CU20220003A7 (es) | Derivados de imidazo[4,5-c]piridina como agonistas de receptores tipo toll | |
| PE20221340A1 (es) | Compuestos heterociclicos | |
| CL2025002367A1 (es) | Compuestos [1,3]tiazolo[4,5-d]-pirimidin-7-onas como inhibidores de la nox4. | |
| ES2107212T3 (es) | Derivados de 1,4-benzoxazina como abridores de los canales de potasio. | |
| AR111176A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos | |
| CO2024017526A2 (es) | Compuestos de degradación de wee1 y usos de los mismos | |
| MX2024012192A (es) | Formas de sal y solvatos de antagonistas de mci-1 | |
| UY40218A (es) | Formas amorfas y cristalinas de los antagonistas de mci-1 | |
| CL2024002532A1 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| CL2024003580A1 (es) | Formas sólidas de un compuesto derivado de heterociclilamida como inhibidores de irak4. | |
| CL2025000424A1 (es) | Formulaciones que comprenden g-csf y usos de las mismas. | |
| CR20250260A (es) | Formas sólidas de compuestos de naftiridina |